ArticleFrontiers in immunology2026
Baihe Gujin decoction ameliorates sepsis-induced acute lung injury through Nrf2/GPX4-mediated antioxidant defense and PPARα-driven metabolic reprogramming: a multi-omics investigation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis-induced acute lung injury (ALI) represents the earliest and most severe complication of sepsis, with extraordinarily high mortality rates. Baihe Gujin decoction (BHGJD), a classical traditional Chinese medicine formula, has demonstrated protective effects against various pulmonary diseases, yet its therapeutic potential in sepsis-induced ALI remains unexplored. Methods: The chemical constituents of BHGJD were characterized by mass spectrometry, and potential protective mechanisms were predicted using network pharmacology. Results: BHGJD significantly ameliorated CLP-induced ALI, as evidenced by improved histological architecture and reduced inflammatory cytokine levels. Integrated multi-omics analysis and experimental validation revealed three interconnected protective mechanisms: 1) activation of an Nrf2/GPX4-associated antioxidant response, initially suggested by glutathione pathway enrichment, reduced lipid peroxidation-related metabolites, and restoration of redox and mitochondrial homeostasis; 2) PPARα/CPT1A-associated metabolic remodeling toward fatty acid utilization, supported by fatty acid transport/metabolism enrichment, coordinated changes in multiple acylcarnitine species, increased PPARα/CPT1A expression, and improved palmitate-supported mitochondrial respiration Conclusion: BHGJD alleviates sepsis-induced ALI through coordinated enhancement of Nrf2/GPX4-associated antioxidant defense, PPARα/CPT1A-linked metabolic reprogramming toward fatty acid utilization, and suppression of inflammatory lipid mediators. These findings provide an integrated mechanistic framework for the protective actions of BHGJD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.